Clinical Trial

A Potential New Option for Targeted Treatment of Pancreatic Cancer is on the Horizon

TIGeR-PaC is Enrolling Patients Across the Country

The TIGeR-PaC clinical trial is currently enrolling newly-diagnosed locally advanced pancreatic cancer patients. TIGeR-PaC is a randomized study of Trans-Arterial Micro-Perfusion (TAMP) versus systemic chemotherapy. The goal of the trial is to prove extended median survival and improved quality of life through targeted delivery of therapy.

Candidate Criteria

Candidate patients must meet the following criteria:

  • Histologically-confirmed pancreatic cancer with initial diagnosis within 6 weeks of consent
  • Not a candidate for surgery
  • No prior therapy for pancreatic cancer

If you meet the criteria or have questions about the TIGeR-PaC trial, contact RenovoRx. For more information visit

Learn more about the risk factors and early warning signs of pancreatic cancer, the importance of clinical trials for Stage III Locally Advanced Pancreatic Cancer patients and more about the TIGeR-PaC clinical trial at

Active Clinical Sites

United States
  • Use  to zoom in and out on the map.
  • Use  by clicking with your cursor and holding down to move map to view locations.
  • Click on  to hide the list of cities.
  • Click on individual cities in the list to remove their location pins from the map.
  • Click on individual pins on the map to view site details

Increasing Published Research Demonstrates RenovoCath’s Utility for Targeted Treatment of Pancreatic Cancer with Improved Safety and Survival